| Vivian Carolina Romero Romero, MD | |
|
25 Michigan St Ne, Suite 5200, Grand Rapids, MI 49503-2515 | |
| (616) 391-3681 | |
| (616) 391-8670 |
| Full Name | Vivian Carolina Romero Romero |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 24 Years |
| Location | 25 Michigan St Ne, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245432368 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301086388 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrum Health Primary Care Partners | 4587568647 | 1585 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Entity Name | Spectrum Health Primary Care Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235188673 PECOS PAC ID: 4587568647 Enrollment ID: O20031121000091 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Entity Name | Spectrum Health Hospitals |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558407189 PECOS PAC ID: 8921904764 Enrollment ID: O20040120000997 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Entity Name | Metropolitan Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811937519 PECOS PAC ID: 5597651836 Enrollment ID: O20040507000012 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Entity Name | Memorial Medical Center Of West Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972589489 PECOS PAC ID: 3678543659 Enrollment ID: O20071128000647 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vivian Carolina Romero Romero, MD 100 Michigan St Ne, Mc 845, Grand Rapids, MI 49503-2560 Ph: (616) 486-6790 | Vivian Carolina Romero Romero, MD 25 Michigan St Ne, Suite 5200, Grand Rapids, MI 49503-2515 Ph: (616) 391-3681 |
News Archive
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tavenner, who oversees the agency responsible for developing Healthcare.gov, apologized for the many problems consumers are encountering as Republicans expand their concerns.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
› Verified 5 days ago
Dr. Marcos Itamar Cordoba Munoz, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25 Michigan St Ne, Maternal Fetal Medicine Dept, Grand Rapids, MI 49503 Phone: 616-391-3681 | |
Erin Michelle Fricke, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25 Michigan St Ne Ste 5200, Grand Rapids, MI 49503 Phone: 616-391-3681 | |
Geron D Turke, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1787 Grand Ridge Ct Ne, Suite 201, Grand Rapids, MI 49525 Phone: 616-913-8601 | |
Lisa Anne Andersson-zetye, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2750 E Beltline Ave Ne Fl 1, Grand Rapids, MI 49525 Phone: 616-447-5850 | |
Dr. Andrea C Wolfe, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 329 Saddleback Dr Ne, Grand Rapids, MI 49525 Phone: 616-486-6790 | |
Dr. Mili Thakur, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3230 Eagle Park Dr Ne Ste 100, Grand Rapids, MI 49525 Phone: 616-988-2229 | |
Dr. Gordon Oliver Downey, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 145 Michigan St Ne, Suite 6300, Grand Rapids, MI 49503 Phone: 616-486-6000 Fax: 616-486-2065 |